GLS1 Inhibitor Screening Assay Kit

Catalog #
79596
$840 *
Size: 96 Reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The GLS1 Inhibitor Screening Assay Kit is designed to measure the hydrolase activity of GLS1 for screening and profiling applications.

Need us to run inhibitor screens or profile your compounds against GLS1? Check out our Metabolic Enzyme Screening Services

This product has been cited 2 times.

Synonyms
glutaminase, glutaminase transcript variant 1, GLS1, GAC, GAM, KGA, GLS., activity assay kit
Product Info
Storage and Usage
Citations2
Assay Kit Format
Fluorogenic
Supplied As
The GLS1 assay kit comes in a convenient 96-well format, with purified GLS1, its substrates, the Coupling reagent, and GLS1 buffer for 100 enzyme reactions. In addition, the kit includes the GLS1 inhibitor CB-839 for use as a control inhibitor.
Materials Required But Not Supplied
  • 0.5 M DTT in aqueous solution
  • Adjustable micropipettor and sterile tips
  • Fluorescent microplate reader capable of reading excitation = 340 nm; emission = 460 nm 
Format
Catalog Number Component Amount Storage
71102 GLS1, His-tag ** 1 µg -80 °C

Avoid

freeze/
thaw

cycles! 
  L-Glutamine (100 mM) 100 µl -20 °C 
  NAD+ (20mM) 1 ml -20 °C 
  Coupling reagent 10 µl -20 °C 
79948 4X GLS assay buffer* 2.5 ml -20 °C 
  CB-839 (100 µM) 20 µl -20 °C 
 79685 96-well black microplate  1  Room Temp.
 

 

 

 

 

 

 

 

 

 

 

 

** The concentration of GLS1 is lot-specific and will be indicated on the tube containing the enzyme.

* Add 20 µl of 0.5 M DTT to 2.5 ml 4X GLS1 assay buffer before use.

UniProt #
O94925
Background
Kidney-type glutaminase (GLS1) is a phosphate-activated amidohydrolase that catalyzes the hydrolysis of L-glutamine to L-glutamate and ammonia. GLS1 is primarily expressed in the brain and kidney where it catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine. It plays an essential role in generating energy for metabolism, synthesizing the brain neurotransmitter glutamate and maintaining acid-base balance in the kidney.
References

1. Mates, J. M., et al. (2013). Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Current Molecular Medicine 13(4): 514-534.
2. Gross, Matthew I., et al. (2014). Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Molecular Cancer Therapeutics 13(4): 890-901.